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The pharmacological potential of vanadium compounds is of great interest to researchers in 
treatments of various diseases (diabetes, cancer, tropical endemic diseases, etc.) [1,2]. On the 
basis of the potential biological/pharmacological applications, in this work we have 
synthesized and physico-chemically characterized, two new complexes containing vanadium 
(IV) and (V) with 4-aminobenzoic acid as the ligand (L). The experimental results obtained 
(elemental analysis, FTIR, diffuse reflectance and UV-vis spectroscopy, EPR and 1HNMR) as 
well as the theoretical calculations (DFT) performed allowed us to determine the following 
stoichiometries [VO(O2)LH2O].H2O (1) and cis-[VOL2H2O] (2). The inhibitory effects on 
acid phosphatases (AcP) and alkaline phosphatases (ALP) were determined. The complexes 
demonstrated specific activities: (2) better inhibitor of AcP (IC50 = 250 μM), (1) higher 
inhibition on ALP (IC50 = 500 μM). The pro-oxidant, antioxidant and anti-leishmaniasis 
activities were also studied. Only (1) catalyzes the oxidation of dihydrorhodamine (DHR) but 
none of them manifests activity against L. amazonensis promastigotes. Both complexes 
catalyzed the dismutation of superoxide (IC50(1) = 114.0 μM, kMcF = 1.6 x105 M-1.s-1, IC50(2) 
= 155.0 μM, kMcF = 1.1x105 M-1.s-1), showing a moderate effect and also mimicked 
peroxidase activity (phenol red, (1) Vmax = 8.34 x 10-5  min-1, Km = 3.29 x 10-4 M, kcat = 3.48 
min-1, kcat/Km=10577.5 M- .min-1; (2) Vmax = 3.44 x 10-5 M.min-1, Km=1.35x10-4 M, kcat =1.43 
min-1, kcat/Km = 10592.6 M-1.min-1). Interaction with albumin will also be discussed. 
Both complexes resulted with potential pharmacological activities in some of the aspects 
studied. 
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